Eisai reports positive hepatocellular carcinoma data for Lenvima

Eisai has announced data from a phase III clinical trial showing the benefits of its anticancer drug Lenvima in the treatment of unresectable hepatocellular carcinoma.

Results from Study 304 highlighted the efficacy and safety of Eisai's drug compared to an established therapy as a first-line treatment for patients with unresectable hepatocellular carcinoma.

The lenvatinib treatment not only met the statistical criteria for noninferiority in terms of overall survival compared to the comparator therapy, but showed statistically significant and clinically meaningful improvements for progression-free survival, time to progression and objective response rate.

Common adverse events were also shown to be consistent with the known side-effect profile of the drug. Based on these findings, Eisai will submit regulatory applications for Lenvima in this indication in the coming months.

The company said: "Eisai remains committed to providing further clinical evidence for lenvatinib aimed at maximising value of the drug as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.